Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 15,655 shares at $38.31 ($598K) on 2021-10-20, disclosed to the SEC on 2021-10-21.
Open-market sale of $598k KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.05 | 1,323 | $50K | 8.4% |
| 2 | $38.05 | 1,323 | $50K | 8.4% |
| 3 | $38.05 | 2,029 | $77K | 12.9% |
| 4 | $38.05 | 2,029 | $77K | 12.9% |
| 5 | $38.49 | 460 | $18K | 3.0% |
| 6 | $38.49 | 704 |
| $27K |
| 4.5% |
| 7 | $37.55 | 148 | $6K | 0.9% |
| 8 | $37.55 | 229 | $9K | 1.4% |
| 9 | $38.31 | 1,463 | $56K | 9.4% |
| 10 | $38.31 | 1,463 | $56K | 9.4% |
| 11 | $38.31 | 2,242 | $86K | 14.4% |
| 12 | $38.31 | 2,242 | $86K | 14.4% |
| Total | $38.19 avg | 15,655 | $598K | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |